<DOC>
	<DOCNO>NCT02480881</DOCNO>
	<brief_summary>This open-label , single sequence , 4-cycle , 4-treatment , drug-drug interaction ( DDI ) study healthy female subject oral contraceptive ( OC ) . There formal research hypothesis statistically test . It expect coadministration BMS-663068 OC affect pharmacokinetics ( PK ) either ethinyl estradiol ( EE ) norethindrone ( NE ) .</brief_summary>
	<brief_title>A Drug-drug Interaction Study Between BMS-663068 Oral Contraceptives Healthy Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norinyl</mesh_term>
	<mesh_term>Norethindrone acetate , ethinyl estradiol , ferrous fumarate drug combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<criteria>Healthy female nonsmoking subject , age 18 40 year , inclusive body mass index 18.0 kg/m2 32.0 kg/m2 , inclusive Women child bear potential intact ovarian function medical history history regular menstrual cycle must stable regimen combination oral contraceptive contain EE progestin ( 28 day regimen ) without evidence breakthrough bleed spot least 2 consecutive month prior Day 1 Any significant acute chronic medical illness Other protocol define exclusion criterion could apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>